Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

被引:271
|
作者
Marraa, Christina M. [1 ]
Zhao, Yu [2 ]
Clifford, David B. [3 ]
Letendre, Scott [4 ]
Evans, Scott [2 ]
Henry, Katherine [5 ]
Ellis, Ronald J. [6 ]
Rodriguez, Benigno [7 ]
Coombs, Robert W. [8 ,9 ]
Schifitto, Giovanni [10 ,11 ]
McArthur, Justin C. [12 ,13 ,14 ]
Robertson, Kevin [15 ]
机构
[1] Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Seattle, WA 98104 USA
[2] Harvard Univ, Stat & Data Management Ctr, Boston, MA 02115 USA
[3] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[4] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[5] NYU, Dept Neurol, New York, NY 10016 USA
[6] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
[7] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[8] Univ Washington, Dept Med, Sch Med, Seattle, WA 98104 USA
[9] Univ Washington, Dept Lab Med, Sch Med, Seattle, WA 98104 USA
[10] Univ Rochester, Dept Neurol, Rochester, NY USA
[11] Univ Rochester, Dept Imaging Sci, Rochester, NY USA
[12] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA
[13] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21218 USA
[14] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA
[15] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA
关键词
antiretroviral therapy; cerebrospinal fluid; cognition; HIV; neuropsychological tests; CENTRAL-NERVOUS-SYSTEM; VIRUS TYPE-1 RNA; COGNITIVE IMPAIRMENT; INFECTION; DEMENTIA; INDIVIDUALS; BRAIN; DRUGS;
D O I
10.1097/QAD.0b013e32832c4152
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition. Design: Multisite longitudinal observational study. Setting: Research clinics. Study participants: One hundred and one individuals with advanced HIV beginning or changing a new potent antiretroviral regimen were enrolled in the study. Data for 79 participants were analyzed. Participants underwent structured history and neurological examination, venipuncture, lumbar puncture, and neuropsychological tests at entry, 24, and 52 weeks. Intervention: Antiretroviral regimens were categorized as CNS penetration effectiveness (CPE) rank of at least 2 or less than 2. Generalized estimating equations were used to examine associations over the course of the study. Main outcome measures: Concentration of HIV RNA in CSF and blood and neuropsychological test scores (NPZ4 and NPZ8). Results: Odds of suppression of CSF HIV RNA were higher when CPE rank was at least 2 than when it was less than 2. Odds of suppression of plasma HIV RNA were not associated with CPE rank. Among participants with impaired neuropsychological performance at entry, those prescribed regimens with a CPE rank of at least 2 or more antiretrovirals had lower composite NPZ4 scores over the course of the study. Conclusion: Antiretroviral regimens with good CNS penetration, as assessed by CPE rank, are more effective in controlling CSF (and presumably CNS) viral replication than regimens with poorer penetration. In this study, antiretrovirals with good CNS penetration were associated with poorer neurocognitive performance. A larger controlled trial is required before any conclusions regarding the influence of specific antiretrovirals on neurocognitive performance should be made. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:1359 / 1366
页数:8
相关论文
共 50 条
  • [31] Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy
    Winston, Alan
    Arenas-Pinto, Alejandro
    Stoehr, Wolfgang
    Fisher, Martin
    Orkin, Chloe M.
    Aderogba, Kazeem
    De Burgh-Thomas, Andrew
    O'Farrell, Nigel
    Lacey, Charles J. N.
    Leen, Clifford
    Dunn, David
    Paton, Nicholas I.
    PLOS ONE, 2013, 8 (04):
  • [32] Characterization of monocytes in cerebrospinal fluid of HIV-infected persons on and off antiretroviral therapy
    Neuenburg, Jutta K.
    Nilsson, Annelie
    Grant, Robert M.
    Price, Richard W.
    JOURNAL OF NEUROVIROLOGY, 2004, 10 : 78 - 78
  • [33] Cerebrospinal fluid HIV RNA in persons living with HIV
    Di Carlofelice, M.
    Everitt, A.
    Muir, D.
    Winston, A.
    HIV MEDICINE, 2018, 19 (05) : 365 - 368
  • [34] Combination antiretroviral therapy for HIV infection
    Maenza, J
    Flexner, C
    AMERICAN FAMILY PHYSICIAN, 1998, 57 (11) : 2789 - 2798
  • [35] Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women
    Cohen, RA
    Boland, R
    Paul, R
    Tashima, KT
    Schoenbaum, EE
    Celentano, DD
    Schuman, P
    Smith, DK
    Carpenter, CCJ
    AIDS, 2001, 15 (03) : 341 - 345
  • [36] Elevated HIV RNA levels in cerebrospinal fluid predict increased subsequent risk for the development of neurocognitive disorders
    Ellis, RJ
    McCutchan, JA
    Heaton, RK
    Letendre, SL
    Spector, SA
    Marcotte, TD
    Hsia, K
    Dawson, LK
    Cherner, M
    Grant, I
    NEUROLOGY, 1999, 52 (06) : A253 - A253
  • [37] HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa?
    Collier, Dami Aderonke
    Haddow, Lewis
    Brijkumar, Jay
    Moosa, Mahomed-Yunus S.
    Benjamin, Laura
    Gupta, Ravindra K.
    BRAIN SCIENCES, 2018, 8 (10)
  • [38] Cerebrospinal fluid acts as an independent viral dynamic compartment in some subjects with HIV-1 infection initiating combination antiretroviral therapy
    Ellis, RJ
    Spector, SA
    Hsia, K
    Grant, I
    McCutchan, JA
    NEUROLOGY, 1998, 50 (04) : A248 - A248
  • [39] Cerebrospinal fluid HIV RNA escape syndrome
    Nasse, Sian
    Underwood, Jonathan
    Hughes, Tom A. T.
    PRACTICAL NEUROLOGY, 2024, 24 (06) : 507 - 510
  • [40] PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy
    Jaime H. Vera
    Basil Ridha
    Yvonne Gilleece
    Aliza Amlani
    Patrick Thorburn
    Sabina Dizdarevic
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 895 - 902